Loading…
Metagenomi Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -90.3% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $1.62 | $3.61 | |
| P/S | — | 2.4x | 2.6x |
| P/B | — | 0.4x | 0.6x |
| EPS | -$2.36 | -$2.36 | |
| Profit margin | — | -348.54% | -149.26% |
| ROE | — | -55.40% | -33.24% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| FLNAFilana Therapeutics Inc | $0.93 | — | 0.7x | — | -55.78% | $44.88M |
| TVGNTevogen Inc. | $6.89 | — | — | — | — | $44.86M |
| QTIQt Imaging Holdings Inc | $3.09 | — | 19.0x | — | -2125.30% | $45.23M |
| GRCEGrace Therapeutics, Inc. | $2.12 |
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Company description provided by Yahoo Finance.
| — |
| 0.7x |
| — |
| -36.19% |
| $44.6M |
| MLSSMilestone Scientific Inc | $0.50 | — | 12.9x | — | -121.67% | $44.55M |
| EDSAEdesa Biotech, Inc. | $4.62 | — | 112.7x | — | -122.93% | $44.54M |